Details of the Drug
General Information of Drug (ID: DMETDQC)
| Drug Name |
1-Benzyl-4-methyl-piperazine
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
1-benzyl-4-methylpiperazine; 62226-74-8; 1-benzyl-4-methyl-piperazine; CHEMBL363603; Piperazine, 1-methyl-4-(phenylmethyl)-; 4-Benzyl-1-methylpiperazine; 1-Benzyl-4-methylpiperazinehydrochloride; PubChem10987; AC1LG1B6; Cambridge id 5263722; N-benzyl-N'-methylpiperazine; SCHEMBL221139; Methyl piperazine, polymer-bound; CTK2C4522; DTXSID90354100; Methyl piperazinomethyl polystyrene; MolPort-000-882-836; MLJOKPBESJWYGL-UHFFFAOYSA-N; HMS1579O15; BCP22253; MFCD00976530; ZINC19536830; STK115879; BDBM50174044
|
||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 190.28 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 1.8 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


